At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
erythropoietindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits (NIMBUS Trial)
In Brief
A Phase 2 clinical trial evaluating erythropoietin for Angiogenesis and Ischemic Stroke. Completed, enrolled 44 participants.
Detailed Summary
Neovascularization Induced by Mechanical Barrier disrUption and Systemic erythropoietin in patients with cerebral perfusion deficits (NIMBUS trial)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAngiogenesis, Ischemic Stroke
Countries--
CollaboratorsDong-A Pharmaceutical Co., Ltd.
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartJul 2016
Primary CompletionJul 2019
Study CompletionDec 2019
TodayJul 2026
First PostedNov 11, 2015
Enrollment StartJul 15, 2016
Primary CompletionJul 16, 2019
Study CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 10.6 years ago
Interventions
erythropoietindrug